Dry Eye Disease

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Dry eye disease (also called dry eye syndrome, keratoconjunctivitis sicca, or ocular surface disease) is one of the most common reasons people see an eye doctor. It happens when your eyes either do not make enough tears, or the tears they make evaporate too quickly, or both. The result is a tear film that no longer keeps the front surface of the eye smooth, comfortable, and clear.

If you have dry eye, your eyes may feel gritty, sandy, burning, or tired, your vision may go blurry and then clear again when you blink, and your eyes may struggle through a long day at a screen. It is easy to dismiss these symptoms as minor, and many people do for years. But dry eye is a real, chronic medical condition that the international expert panel TFOS DEWS II (the second Tear Film and Ocular Surface Society Dry Eye Workshop) defined in 2017 as a disease of the ocular surface marked by loss of tear-film stability, tear hyperosmolarity (saltier-than-normal tears), inflammation and damage to the surface, and abnormal sensation of the nerves on the eye.

The good news is that dry eye is almost always manageable. There is no single magic cure, but there is a well-tested ladder of treatments — from simple, cheap artificial tears and warm compresses, through prescription anti-inflammatory drops, all the way to newer FDA-approved sprays and drops. This page explains, in plain language, what is actually going on in a dry eye, what the honest evidence says about each treatment (including the much-debated question of whether omega-3 fish oil works), and when grittiness is something you should get checked rather than just put up with.

2. Epidemiology

Dry eye is extremely common. Depending on how strictly it is defined, population studies estimate that anywhere from roughly 5% to 50% of adults have it, with most large reviews landing around 5–30% of people over age 50. The wide range exists because some studies count only people with both symptoms and objective signs, while others count anyone reporting symptoms. The TFOS DEWS II Epidemiology Report concluded that the prevalence rises steadily with age and is consistently higher in women than in men.

Two trends are pushing those numbers up:

An aging population. Tear production naturally declines with age, and dry eye becomes much more common after the 50s and 60s.
Screens. Hours of staring at phones, tablets, and computers cut your blink rate dramatically, and dry eye is now showing up earlier in life — including in teenagers and young adults who spend most of their waking hours on devices.

Dry eye is also one of the most common reasons for an eye-clinic visit and a frequent reason people stop wearing contact lenses. Because it is so common and so under-reported, the true burden — on comfort, on reading and driving, and on quality of life — is almost certainly larger than the official figures suggest.

3. Pathophysiology

To understand dry eye, it helps to picture the tear film — the thin, three-layered coating that covers the front of your eye and is renewed every time you blink. It has three layers, each made by a different structure:

An oily (lipid) outer layer, made by the meibomian glands in your eyelids. This layer is like a lid on a pot — it slows evaporation and keeps the watery tears from drying off too fast.
A watery (aqueous) middle layer, made by the lacrimal glands. This is the bulk of the tear, carrying oxygen, nutrients, and antibacterial proteins to the surface.
A sticky (mucin) inner layer, made by goblet cells in the conjunctiva. This layer helps the watery tears spread evenly and cling to the eye's surface.

Dry eye begins when any of these layers fails. This leads to a self-feeding cycle that the experts call the vicious circle of dry eye:

The tear film becomes unstable and breaks up too quickly between blinks.
Areas of the surface are left exposed, and the remaining tears become hyperosmolar — too salty — as water evaporates away.
Salty, concentrated tears irritate and stress the surface cells, triggering inflammation.
Inflammation damages the tear-producing cells, the goblet cells, and the surface nerves — which makes the tear film even less stable, and the circle continues.

This inflammatory loop is why simply adding water (artificial tears) helps symptoms but often does not "cure" the underlying disease — and why anti-inflammatory drops were a major advance.

The two main types. Dry eye is split into two overlapping forms, and knowing which one you have guides treatment:

Aqueous-deficient dry eye — the lacrimal glands simply do not make enough watery tears. This is the form most strongly linked to Sjögren's syndrome and other autoimmune conditions, in which the immune system attacks the tear and saliva glands.
Evaporative dry eye — enough watery tears are made, but they evaporate too fast because the oily layer is poor. The usual cause is meibomian gland dysfunction (MGD), in which the oil glands in the lids get clogged and stop releasing healthy oil. Evaporative dry eye driven by MGD is by far the most common form, accounting for the majority of cases.

In real life, most people have a mix of both — which is why doctors now talk about dry eye as a spectrum rather than two separate boxes.

The watery-eye paradox. One of the most confusing things about dry eye is that it can make your eyes water. When the surface gets dry and irritated, the nerves send a distress signal that triggers a burst of reflex tearing — a flood of low-quality, watery tears with little oil. These reflex tears spill over the lids instead of coating the eye properly, so the eye feels wet and dry at the same time. People often arrive at the clinic insisting they cannot possibly have "dry" eye because their eyes keep watering — and they are surprised to learn that excessive watering is a classic dry-eye symptom.

4. Etiology and Risk Factors

Dry eye usually has more than one cause stacked on top of each other. The most important risk factors are:

Age. Tear production falls with age; dry eye is common after 50 and very common after 65.
Female sex and hormonal change. Women are affected more often, and risk rises around menopause when sex-hormone levels shift. Pregnancy and oral contraceptives can also play a role.
Screen use. Concentrating on a screen drops your blink rate by more than half, leaving the tear film to evaporate between blinks. This is now a leading driver of dry eye in younger people.
Contact lenses. Lenses disrupt the tear film and are a frequent cause of dry, uncomfortable eyes — often the reason people give up on contacts.
Eye surgery. LASIK and other corneal procedures cut surface nerves and commonly cause temporary (and occasionally long-lasting) dry eye. Cataract surgery can do the same.
Medications. Many common drugs reduce tear production, including antihistamines (allergy pills), antidepressants (especially older tricyclics and some SSRIs), diuretics (water pills), beta-blockers, and certain acne medicines (isotretinoin). Decongestants and some anti-anxiety drugs add to the load.
Autoimmune and inflammatory disease. Sjögren's syndrome is the classic cause of severe aqueous-deficient dry eye, but rheumatoid arthritis, lupus, and thyroid eye disease (linked to Graves' disease) are all associated with it.
Skin and lid conditions. Rosacea and blepharitis (chronic lid-margin inflammation) clog the meibomian glands and are a major cause of evaporative dry eye.
Environment. Low humidity, wind, air conditioning, forced-air heating, ceiling fans, smoke, and high altitude all speed up tear evaporation.
Diet and general health. Low intake of omega-3 fats, vitamin A deficiency (in some settings), poor sleep, and dehydration can all contribute.

5. Clinical Presentation

Dry eye produces a cluster of symptoms that wax and wane over the day. The most common are:

Grittiness or a foreign-body sensation — the feeling that there is sand or an eyelash in the eye when there is nothing there.
Burning, stinging, or aching.
Fluctuating, intermittent blur — your vision smears or goes soft, then sharpens for a moment after you blink. This happens because an unstable tear film is also your eye's outermost lens.
Tired, heavy eyes, especially late in the day.
Redness and a feeling of irritation.
Light sensitivity (photophobia).
Contact-lens intolerance — lenses that used to be comfortable now feel scratchy after a couple of hours.
Watery eyes — paradoxically, reflex tearing from an irritated dry surface (see the watery-eye paradox above).
Stringy mucus in or around the eyes.

What makes it worse is a useful clue: dry-eye symptoms typically flare with screen time, reading, wind, air conditioning, dry indoor heating, airplanes, and air travel, and ease in humid environments or after sleep. A strong link to screens points to the blink mechanism.

The screen mechanism — and the 20-20-20 rule. When you focus hard on a screen, your blink rate drops from a normal ~15 blinks a minute to as few as 5, and many of those blinks are incomplete (the lid does not fully close, so the lower oil glands are not "wiped" across the eye). Each missed blink lets the tear film thin and evaporate. The simplest, free intervention is the 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds — and, while you are at it, blink fully a few times. Lowering your screen so you look slightly down at it also helps, because a downward gaze narrows the eye opening and reduces the exposed, evaporating surface.

6. Diagnosis

There is no single perfect test for dry eye, so eye doctors combine a few. Importantly, symptoms and signs often do not match — some people have severe symptoms with a near-normal-looking surface, and others have a damaged surface with few complaints — so the diagnosis rests on the whole picture, not one number.

Symptom questionnaires. Validated scores such as the OSDI (Ocular Surface Disease Index) or DEQ-5 put a number on how much your eyes bother you and track whether treatment is helping.
Tear break-up time (TBUT). A drop of fluorescein dye is added, and the doctor times how many seconds the tear film stays smooth before dry spots appear. A break-up under about 10 seconds suggests an unstable film; non-invasive versions avoid the dye.
Tear osmolarity. A tiny sample measures how "salty" your tears are. A high or unequal value between the two eyes points to dry eye, reflecting the hyperosmolarity at the heart of the disease.
Ocular surface staining. Dyes (fluorescein, lissamine green) highlight damaged or dead cells on the cornea and conjunctiva, showing where the surface has been injured.
Schirmer's test. A small paper strip tucked under the lower lid measures how much it wets in 5 minutes — a rough gauge of watery-tear production, most useful for the aqueous-deficient form.
Meibography and lid evaluation. Infrared imaging photographs the meibomian glands inside the lids to see whether they are shortened, dropped out, or blocked — the key test for diagnosing MGD. The doctor will also press on the lids to see what kind of oil comes out.

The doctor will also look for treatable underlying causes — blepharitis, rosacea, Sjögren's, thyroid eye disease, or drying medications — because treating the root cause often matters more than the drops.

7. Treatment

Dry-eye treatment is a ladder: you start with the simplest measures and add stronger ones only if needed. The right rung depends on which type you have and how severe it is. Here is the honest, evidence-based version.

Step 1 — Lubricate: artificial tears

Artificial tears are the foundation of treatment and are available without a prescription. They top up the tear film and relieve symptoms. Two practical points:

If you use drops more than about 4 times a day, choose preservative-free tears. The preservatives in many multi-dose bottles can themselves irritate the surface with frequent use. Preservative-free single-use vials cost more but are gentler for heavy users.
Thicker gels and ointments last longer (good for nighttime) but blur vision, so they are best at bedtime.

Step 2 — Unblock the oil glands: warm compresses and lid hygiene (for MGD)

If your dry eye is the common evaporative/MGD type, the most useful home treatment targets the lid oil glands:

Warm compresses — a warm (not hot) pack or microwavable eye mask held on closed lids for several minutes softens the hardened oil so it can flow again.
Lid hygiene — gentle cleaning of the lid margins with a clean warm cloth or a dedicated lid wipe clears debris and bacteria that worsen blepharitis.
A gentle lid massage after the warm compress helps express the softened oil.

In-office procedures (thermal pulsation devices, manual gland expression, intense pulsed light for rosacea-associated MGD) are options when home care is not enough.

Step 3 — Omega-3 supplements: an honest look at the controversy

This is where you should be skeptical of confident claims either way. For years, omega-3 fish-oil supplements were widely recommended for dry eye, supported by several smaller positive trials and a plausible anti-inflammatory mechanism. A 2019 meta-analysis (Giannaccare and colleagues) pooling those trials concluded that omega-3 supplementation improved dry-eye symptoms and some signs.

But in 2018, the large, rigorous, NIH-funded DREAM trial — published in the New England Journal of Medicine, with 535 patients followed for a year — found that high-dose omega-3 (3,000 mg/day) was no better than an olive-oil placebo for moderate-to-severe dry eye. Both groups improved similarly. This well-designed null result seriously challenged the earlier enthusiasm.

The honest bottom line: the evidence is genuinely mixed and unresolved. Omega-3 supplements are not a proven treatment, and the best single trial was negative. They are reasonable to try if you wish — they are inexpensive and generally safe — but go in with modest expectations, and getting omega-3s from oily fish and a balanced diet is at least as sensible as high-dose capsules.

Step 4 — Calm the inflammation: prescription drops

Because inflammation drives the vicious circle, prescription anti-inflammatory drops are a major step up for persistent dry eye:

Cyclosporine (e.g., Restasis, Cequa) — a topical immune-modulating drop that, over weeks to months, increases the eye's own tear production. The landmark trials (Sall and colleagues, 2000) established its benefit. It can sting at first and takes patience to work.
Lifitegrast (Xiidra) — a different anti-inflammatory drop (an LFA-1 antagonist) shown in trials such as OPUS to improve both dryness symptoms and surface signs. A temporary odd taste and stinging are the common downsides.
Short courses of topical steroids are sometimes used to break a bad flare quickly, but only under supervision because of risks (raised eye pressure, cataract) with long-term use.

Step 5 — Keep the tears in: punctal plugs

Tiny punctal plugs inserted into the drainage holes at the inner corner of the lids block tears from draining away, keeping your natural tears on the eye longer. They are a quick, reversible office procedure, most useful for the aqueous-deficient type.

Step 6 — Newer FDA-approved options

Varenicline nasal spray (Tyrvaya) — a spray in the nose, not the eye, that stimulates a nerve pathway to make your own tears. The phase-3 ONSET-2 trial (Wirta and colleagues, 2022) showed meaningfully increased tear production versus a control spray.
Perfluorohexyloctane (Miebo) — a preservative-free, water-free eye drop that forms a thin film slowing evaporation, designed specifically for evaporative dry eye from MGD. The phase-3 GOBI trial (Tauber and colleagues, 2023) showed it improved both signs and symptoms versus saline.

Step 7 — Treat the root cause

None of the above works well if an underlying driver is left untreated. That means treating blepharitis and rosacea (sometimes with oral low-dose doxycycline or topical therapy), managing Sjögren's and other autoimmune disease with a rheumatologist, and — with your prescriber — reviewing whether a drying medication (antihistamine, antidepressant, diuretic) can be changed.

When to see a doctor

Most dry eye can be self-managed, but treat the following as reasons to get checked promptly: eye pain, a sudden change in vision, marked or persistent redness, light sensitivity, discharge, or symptoms that do not improve after a couple of weeks of over-the-counter tears. Sudden severe symptoms can signal an infection, corneal damage, or another eye problem that needs professional care — do not just keep adding drops.

8. Complications

Mild dry eye is mostly a comfort and quality-of-life problem, but when it is moderate-to-severe and left untreated it can cause real damage:

Corneal surface damage — persistent dryness erodes the surface cells (punctate keratopathy), and in severe cases can lead to corneal ulcers and scarring that threaten vision.
Eye infections — a healthy tear film is part of the eye's defense; a damaged surface is more prone to infection.
Chronic eye pain and reduced quality of life — constant irritation can interfere with reading, driving, screen work, and sleep, and is associated with anxiety and depression in severe cases.
Unstable, fluctuating vision that interferes with detailed tasks and can complicate the planning of cataract or refractive surgery.
Contact-lens dropout and intolerance.

9. Prognosis

The honest framing is that dry eye is usually a chronic, manageable condition rather than a curable one — more like managing blood pressure than treating a one-time infection. For most people, the right combination of measures keeps symptoms well controlled, and many do very well on simple steps alone (screen breaks, artificial tears, warm compresses).

Outcomes depend on the cause. Dry eye driven by screens, environment, or a drying medication often improves substantially when those factors are addressed. Dry eye from MGD responds well to consistent lid care plus, when needed, newer drops. The most stubborn cases are the severe aqueous-deficient forms tied to Sjögren's syndrome and other autoimmune disease, which need ongoing, layered treatment. The key to a good outcome is consistency — dry-eye treatments work when used regularly, not just during a flare — and addressing the root cause rather than only chasing symptoms.

10. Prevention

You can lower your risk of developing dry eye, or ease existing symptoms, with a handful of practical habits:

Take screen breaks and blink. Use the 20-20-20 rule (every 20 minutes, look 20 feet away for 20 seconds) and make a conscious effort to blink fully. Position screens slightly below eye level so you gaze downward.
Manage your environment. Add a humidifier in dry rooms, steer air vents, fans, and car heaters away from your face, take breaks from air-conditioned and forced-heat spaces, and consider wraparound glasses in wind.
Eat for your tears. A diet that includes omega-3 fats from oily fish, plus plenty of vegetables, is sensible for overall eye and body health — keeping in mind that high-dose supplements are unproven for treating established dry eye.
Stay hydrated and get enough sleep; both support a healthy tear film.
Review your medications with your doctor. If you take antihistamines, antidepressants, or diuretics and have dry eyes, ask whether the dose or drug can be adjusted — never stop a prescribed medicine on your own.
Keep your lids clean if you are prone to blepharitis or rosacea, and don't smoke (or sit in smoke).
Be smart with contacts — take device breaks, follow wear schedules, and tell your eye doctor if lenses become uncomfortable.

11. Recent Research and Advances

Dry-eye research has moved quickly, and the field's center of gravity has shifted from "just add water" toward targeting inflammation, the oil glands, and the tear-stimulating nerves:

A unified definition. The 2017 TFOS DEWS II reports reframed dry eye around tear-film instability, hyperosmolarity, and inflammation, and standardized how it is diagnosed and managed worldwide — the framework most clinicians now use.
Nerve-stimulating therapy. Varenicline nasal spray (Tyrvaya) is a genuinely novel idea — making the body produce its own complete tears via a nerve pathway, rather than dripping substitutes onto the eye.
Anti-evaporative drops. Perfluorohexyloctane (Miebo) is the first drop approved specifically to slow tear evaporation, the dominant problem in MGD-related dry eye.
The omega-3 debate. The contrast between the positive earlier trials and meta-analyses and the negative DREAM trial remains an active, honest controversy — a useful reminder that large, rigorous trials sometimes overturn popular treatments.
Better diagnostics. Tear osmolarity, inflammatory-marker (MMP-9) point-of-care tests, and detailed meibography imaging are helping doctors classify dry-eye type and tailor treatment, and there is growing interest in neuropathic ("pain-without-stain") dry eye where the nerves, not the surface, are the main problem.

12. References & Research

Historical Background

The condition's autoimmune form is named for Swedish ophthalmologist Henrik Sjögren, whose 1933 doctoral thesis described the triad of dry eyes, dry mouth, and arthritis and coined keratoconjunctivitis sicca for the ocular component. For most of the twentieth century, treatment meant little more than lubricating artificial tears, whose formulations were refined steadily from simple saline toward the preservative-free, polymer-based drops used today. A turning point came in 2000, when topical cyclosporine was shown in large randomized trials to treat the underlying inflammation rather than merely the symptoms — ushering in the modern "anti-inflammatory era." The international TFOS Dry Eye Workshop (DEWS) reports of 2007 and 2017 then unified the definition, classification, and management of dry eye worldwide, and the years since have brought nerve-stimulating sprays and anti-evaporative drops.

Key Research Papers

Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017;15:276-283.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II Pathophysiology Report. The Ocular Surface. 2017;15:438-510.
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. The Ocular Surface. 2017;15:334-365.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology Report. The Ocular Surface. 2017;15:539-574.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. The Ocular Surface. 2017;15:575-628.
Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II Iatrogenic Report. The Ocular Surface. 2017;15:511-538.
Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Definition and Classification Subcommittee. Investigative Ophthalmology & Visual Science. 2011;52:1930-1937.
Tomlinson A, Bron AJ, Korb DR, et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Diagnosis Subcommittee. Investigative Ophthalmology & Visual Science. 2011;52:2006-2049.
Sall K, Stevenson OD, Mundorf TK, et al. Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease. Ophthalmology. 2000;107:631-639.
Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease (OPUS-3). Ophthalmology. 2017;124:53-60.
Dry Eye Assessment and Management (DREAM) Study Research Group. n−3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. New England Journal of Medicine. 2018;378:1681-1690.
Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. Cornea. 2019;38:565-573.
Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2022;129:379-387.
Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023;130:516-524.

Research Papers

Dry eye disease is one of the most actively researched areas in eye care. The PubMed topic searches below open live, up-to-date results so you can explore the evidence on diagnosis, the omega-3 controversy, and the newest treatments for yourself.

Connections

Sjögren's Syndrome — the classic autoimmune cause of severe aqueous-deficient dry eye.
Rheumatoid Arthritis — an autoimmune disease frequently associated with dry eye.
Lupus — systemic autoimmune disease that can affect the tear glands and ocular surface.
Glaucoma — preservative-containing pressure drops can worsen dry-eye symptoms.
Cataracts — cataract surgery can trigger or worsen dry eye, and dry eye affects surgical planning.
Macular Degeneration — another age-related eye condition managed in ophthalmology.
Rosacea — a major cause of meibomian gland dysfunction and evaporative dry eye.
Graves' Disease — thyroid eye disease causes lid retraction and exposure-related dry eye.
Hypothyroidism — thyroid dysfunction is associated with tear-film and ocular-surface problems.
Allergies — allergic eye disease and the antihistamines used to treat it both contribute to dryness.
Ophthalmology — overview of eye and vision conditions.
Omega-3 Fatty Acids — the much-debated nutrient at the center of dry-eye supplement research.
Salmon — a dietary source of EPA and DHA omega-3 fats.
All Conditions — browse the full list of health topics.

Back to Table of Contents